However, since IL-2 released by CAR-T-cells negatively impacts the anti-tumor activity through sustaining survival and function of Treg cells, the authors engineered a hybrid receptor, fusing the extracellular IL-7α receptor subunit to the intracellular IL-2β receptor subunit (IL7Rα/IL2Rβ) which converted the IL-7 signal into IL-2 specific response. Here, IL2 is linked to neoplasm.